Dr. George Wang, is currently responsible for Discovery and Preclinical Services at WuXi Biologics.  His oversight covers the contract services of therapeutic proteins from concept to IND filing. Dr. Wang played various leadership roles since he joined WuXi Biologics in 2014, including managing material generation for over 300 discovery projects, initiating the domain antibody group, and establishing several bispecific antibody platforms. He developed the innovative and proprietary WuXiBody® bispecific antibody platform which has been licensed to over 12 clients.

Prior to joining WuXi Biologics, Dr. Wang worked at Bayer Healthcare for nine years as group head. He contributed to several global projects, including leading a project from target to clinical development. He also participated in the evaluation and in-license of new technologies. Before that, Dr. Wang worked as scientist at two biotech start-ups.  Dr. Wang has authored over 20 publications in peer-reviewed journals and is the lead inventor on over 40 patents and patent applications.

Dr. Wang obtained a PhD in oncology from Peking University and an MBA from the University of California at Berkeley. He completed his post-doctoral training at Harvard Medical School.